Q32 Bio Inc. Files 10-K/A Amendment for Fiscal Year Ended December 31, 2023

TL;DR

<b>Q32 Bio Inc. has filed an amended 10-K report for the fiscal year 2023, detailing its corporate information and stock listing.</b>

AI Summary

Q32 Bio Inc. (QTTB) filed a Amended Annual Report (10-K/A) with the SEC on April 12, 2024. Q32 Bio Inc. filed an amended 10-K report for the fiscal year ending December 31, 2023. The company's common stock trades under the symbol QTTB on The Nasdaq Global Market. Q32 Bio Inc. is incorporated in Delaware and its primary executive offices are located in Waltham, MA. The company was formerly known as Homology Medicines, Inc., with a name change effective December 28, 2015. Q32 Bio Inc. is classified under Pharmaceutical Preparations (SIC code 2834).

Why It Matters

For investors and stakeholders tracking Q32 Bio Inc., this filing contains several important signals. This filing provides an updated official record of Q32 Bio Inc.'s financial and operational status for the 2023 fiscal year, crucial for investors and regulatory oversight. The amendment ensures that all required disclosures are accurate and up-to-date, reflecting the company's current standing and compliance with SEC regulations.

Risk Assessment

Risk Level: low — Q32 Bio Inc. shows low risk based on this filing. The filing is an amendment to a previous 10-K, indicating a need for correction or addition to the initial report, but the nature of the amendment is not specified in this excerpt.

Analyst Insight

Review the full amended 10-K filing to understand the specific changes made and their potential impact on Q32 Bio Inc.'s financial and operational outlook.

Key Numbers

• 20231231 — Fiscal Year End (Report period)
• 20240412 — Filing Date (Date of submission)
• 001-38433 — Commission File Number (SEC File Number)
• 473468154 — IRS Number (Employer Identification No.)

Key Players & Entities

• Q32 Bio Inc. (company) — Registrant
• QTTB (company) — Trading Symbol
• The Nasdaq Global Market (company) — Exchange
• Delaware (company) — State of Incorporation
• Waltham, MA (company) — Business Address
• Homology Medicines, Inc. (company) — Former Company Name
• 20151228 (date) — Date of Name Change
• 2834 (company) — Standard Industrial Classification Code

FAQ

Industry Context

Q32 Bio Inc. operates within the pharmaceutical preparations industry, focusing on the development and commercialization of therapeutics.

Regulatory Implications

The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including the filing of annual reports (10-K) and amendments.

What Investors Should Do

1. Analyze the specific amendments made in the 10-K/A filing.
2. Verify the accuracy of corporate and financial information presented.
3. Assess any new disclosures or risk factors introduced in the amendment.

Year-Over-Year Comparison

This is an amended 10-K filing, indicating updates or corrections to the previously submitted annual report for the fiscal year 2023.

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share QTTB The Nasdaq Global Ma

Filing Documents

• d800222d10ka.htm (10-K/A) — 630KB
• d800222dex41.htm (EX-4.1) — 19KB
• d800222dex211.htm (EX-21.1) — 2KB
• d800222dex313.htm (EX-31.3) — 3KB
• d800222dex314.htm (EX-31.4) — 3KB
• d800222dex971.htm (EX-97.1) — 26KB
• 0001193125-24-094768.txt (&nbsp;) — 964KB
• fixx-20231231.xsd (EX-101.SCH) — 5KB
• fixx-20231231_cal.xml (EX-101.CAL) — 1KB
• fixx-20231231_def.xml (EX-101.DEF) — 2KB
• fixx-20231231_lab.xml (EX-101.LAB) — 26KB
• fixx-20231231_pre.xml (EX-101.PRE) — 16KB
• d800222d10ka_htm.xml (XML) — 9KB

: Gender Identity

Part I: Gender Identity Directors 3 1 5

: Demographic Background

Part II: Demographic Background African American or Black Alaskan Native or Native American Asian 1 Hispanic or Latinx Native Hawaiian or Pacific Islander White 2 Two or More Races or Ethnicities LGBTQ+ Did Not Disclose Demographic Background 6 Executive Officers The following table identifies our current executive officers, their current positions with the Company and each executive officer's age as of March 25, 2024. Name Position Held with Q32 Bio Inc. Since Age Executive Officers Jodie Morrison Chief Executive Officer, Secretary and Director 2024 48 Lee Kalowski Chief Financial Officer, President and Treasurer 2024 43 Jason A. Campagna Chief Medical Officer 2024 54 Shelia M. Violette Chief Scientific Officer and President of Research 2024 63 Jodie Morrison . Ms. Morrison's biographical information is disclosed in the section above under the heading "Directors." Lee Kalowski. M.B.A. Mr. Kalowski, age 43, has served as our Chief Financial Officer and President since 2024. Mr. Kalowski previously served as Legacy Q32's Interim Chief Financial Officer since October 2023 and has also served as a consultant to the life sciences industry since October 2023. Prior to joining Q32, Mr. Kalowski served as Chief Financial Officer from July 2017 to June 2023 and as President from January 2019 to June 2023 of Bicycle Therapeutics. Previously, Mr. Kalowski was Chief Financial Officer of Tokai Pharmaceuticals. Prior to Tokai, Mr. Kalowski served in global biotechnology equity research at Credit Suisse, where he covered companies in the biopharmaceutical industry as a Senior Analyst. Mr. Kalowski received a B.A. in biology and economics from Union College and an M.B.A. from The Wharton School of the University of Pennsylvania. Jason A. Campagna, M.D., Ph.D. Dr. Campagna, age 54, has served as our Chief Medical Officer since 2024. Dr. Campagna previously served as the Chief Medical Officer of Legacy Q32, where he had been em

View Full Filing

View this 10-K/A filing on SEC EDGAR